Price
No data yet.
Social Signal Score
Analyst Ratings
5 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Cuong Viet Do
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 13
- Beta
- 0.78
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -53.12
Financials
Net Income
$-5.61MEBITDA
$-5.60MFree Cash Flow
$-2.91MEPS (diluted)
$-0.68Shares Outstanding (diluted)
8.27M+118033.4%Operating Expenses
$5.65MCash & Debt
$7.73MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $0.00 | $-22.07M | $-3.05 |
| 2025 | $0.00 | $-17.54M | $-12.12 |
| 2024 | $0.00 | $-32.12M | $-73.05 |
| 2023 | $0.00 | $-50.26M | $-154.70 |
| 2022 | $0.00 | $-26.08M | $-106.00 |
| 2021 | $0.00 | $-130.25M | $-1482.30 |
| 2020 | $0.00 | $-16.68M | $-685.20 |
| 2019 | $0.00 | $-2.44M | $-98.20 |
| 2018 | $0.00 | $-2.41M | $-317.70 |
| 2017 | $0.00 | $-1.33M | $-186.10 |
| 2016 | $0.00 | $-431.9K | $-61.90 |
| 2015 | $0.00 | $-233.0K | $-33.40 |
| 2014 | $0.00 | $-321.9K | $-46.20 |
| 2013 | $0.00 | $-70.0K | $-0.21 |
Valuation
BIVIhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
60-59.32%Social Signal Score
Mentions (17)
- Newsglobenewswire.com·6d ago·Positive
BioVie Presents New Biomarker Data Highlighting Biomarker-Defined Endotypes and Neuropeptide Y Response to Bezisterim at the 4th Long COVID International Conference 2026 New findings from the Phase 2 ADDRESS-LC trial identify two distinct biomarker-defined Long COVID endotypes 1 associated with different patient responses to bezisterim treatment.
View source ↗ - Newsglobenewswire.com·13d ago·Positive
BioVie Presents New Biomarker Data from the ADDRESS-LC Trial of Bezisterim in Long COVID at the NIH RECOVER-TLC Third Annual Workshop New findings from the Phase 2 ADDRESS-LC trial suggest two distinct biomarker-defined Long COVID endotypes 1 associated with different patient responses to bezisterim treatment. Patients with a high-inflammatory endotype showed improvements in objective cognitive impairment, while those with a low-myeloid endotype experienced improvements in fatigue and post-exert
View source ↗ - Newsglobenewswire.com·18d ago·Negative
…ed Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules CARSON CITY, Nev., Nov. 04, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that it has entered into a securities purchase agreement with a single healthcare focused institutional investor for the purchase and sale of 2,962,500 shares of common sto…
View source ↗ - Newsglobenewswire.com·20d ago·Negative
…sentation of Bezisterim Long COVID Data at the 4th Long COVID International Conference 2026 CARSON CITY, Nev., Nov. 02, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced the Company has been invited to present a late-breaking oral presentation at the 4th Long COVID International Conference 2026 to be held in Nice, France from November 12-13…
View source ↗ - Newsproactiveinvestors.com·33d ago·Negative
BioVie reports positive Phase 2 Parkinson's data for bezisterim BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) said its experimental Parkinson's drug bezisterim improved both motor and non-motor symptoms in a subgroup of early-stage patients with higher systemic inflammation, according to Phase 2 SUNRISE-PD results presented at the American Neurological Association's annual meeting in San Diego. The randomized, double-blind, placebo-controlled trial enrolled 57 patients, who received bezisterim or plac…
View source ↗ - Newsglobenewswire.com·33d ago·Negative
BioVie Presents Data on Bezisterim in Parkinson's Disease at the 2026 American Neurological Association Annual Meeting Parkinson's patients elevated baseline inflammation demonstrated statistically significant improvements in both motor and non-motor symptoms with Bezisterim compared to placebo. CARSON CITY, Nev.
View source ↗ - Newsproactiveinvestors.com·34d ago·Neutral
BioVie says bezisterim eased fatigue and cognitive symptoms in Long COVID subgroups BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) said its Phase 2 ADDRESS-LC trial found that bezisterim delivered the greatest benefits in Long COVID patients with more severe baseline fatigue, post-exertional malaise (PEM) or cognitive impairment, with statistically significant improvements across multiple measures. The results were presented at the American Neurological Association's annual meeting in San Diego, and th…
View source ↗ - Newsproactiveinvestors.com·39d ago·Negative
BioVie to present Long COVID and Parkinson's trial results at American Neurological Association meeting BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) will present results from two Phase 2 trials of its experimental drug bezisterim, in Long COVID and Parkinson's disease, at the American Neurological Association's annual meeting in San Diego. The company said both abstracts were accepted as poster presentations at ANA2026, which runs from October 17 to 20.
View source ↗ - Newsseekingalpha.com·60d ago·Positive
BioVie Inc. (BIVI) Discussion of Phase 2 data on bezisterim in Long COVID and Parkinson's with focus on inflammation targets Transcript BioVie Inc. (BIVI) Discussion of Phase 2 data on bezisterim in Long COVID and Parkinson's with focus on inflammation targets Transcript
View source ↗ - Newsseekingalpha.com·68d ago·Positive
BioVie Inc. (BIVI) Discusses Topline Phase 2 ADDRESS-LC Trial Data and the Potential of Bezisterim in Long Covid Transcript BioVie Inc. (BIVI) Discusses Topline Phase 2 ADDRESS-LC Trial Data and the Potential of Bezisterim in Long Covid Transcript
View source ↗ - Newsglobenewswire.com·68d ago·Positive
BioVie Announces Topline Results from Phase 2 ADDRESS‑LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID Statistically significant benefits observed in bezisterim-treated Long COVID patients in pre-specified subgroups with high baseline fatigue, cognitive impairment, and/or post‑exertional malaise
View source ↗ - Newsglobenewswire.com·69d ago·Positive
BioVie to Host Conference Call to Discuss Topline Data from Phase 2 ADDRESS-LC Trial and the Potential of Bezisterim in Long Covid Conference call scheduled for Tuesday, September 15, 2026, at 8:30 a.m. Eastern Time (ET) Conference call scheduled for Tuesday, September 15, 2026, at 8:30 a.m. Eastern Time (ET)
View source ↗ - Newsproactiveinvestors.com·75d ago·Negative
BioVie advances Parkinson's Phase 3 development program with FDA engagement BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) told investors that it is preparing to advance its Phase 3 development program for bezisterim in Parkinson's disease and has requested an End-of-Phase 2 meeting with the US Food and Drug Administration. The company is working with Parkinson's disease clinical development experts to finalize the design of a Phase 3 trial.
View source ↗ - Newsglobenewswire.com·75d ago·Neutral
BioVie Announces Update to Parkinson's Phase 3 Development Program Company Corresponded with the FDA on an End of Phase 2 Meeting to Align on Phase 3 trial Design for Evaluation of Bezisterim in Early-stage Parkinson's Disease Company Corresponded with the FDA on an End of Phase 2 Meeting to Align on Phase 3 trial Design for Evaluation of Bezisterim in Early-stage Parkinson's Disease
View source ↗ - Newsproactiveinvestors.com·83d ago·Positive
BioVie completes final patient visit in Phase 2 Long COVID trial BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) announced that has completed the last on-treatment visit in its Phase 2 ADDRESS-LC clinical trial evaluating bezisterim in adults with Long COVID, with topline results targeted for release before the end of September 2026. The Carson City, Nevada-based clinical-stage company is developing therapies for neurological and neurodegenerative diseases.
View source ↗ - Newsglobenewswire.com·83d ago·Negative
…C Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID CARSON CITY, Nev., Aug. 31, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that the last on-treatment visit of its ADDRESS-LC Phase 2 trial evaluating bezisterim for the treatment of neurological symptoms of Long COVID has been completed.
View source ↗ - Newsseekingalpha.com·102d ago·Positive
BioVie Inc. (BIVI) Discusses Bezisterim Mechanism of Action and SUNRISE-PD Phase II Trial Design Transcript BioVie Inc. (BIVI) Discusses Bezisterim Mechanism of Action and SUNRISE-PD Phase II Trial Design Transcript
View source ↗
Earnings
Fri, Feb 5(in 2 months)
Typical surprise +2.1% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-0.70 vs $-0.52miss
- Mon, May 11$-0.70 vs $-0.73beat
- Tue, Feb 10$-0.77 vs $-0.81beat
- Mon, Nov 10$-0.98 vs $-0.79miss
- Fri, Aug 15$-1.82 vs $-1.82beat
- Mon, May 12$-1.50 vs $-3.20beat
Estimates and results for BIVI via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by BIVI officers and directors.
- Bought
- $4.0m
- Sold
- $353k
12 trades
8 trades
- Do Cuong Vbought
- Do Cuong Vbought
- Palumbo Joseph Mbought
- Chappell Amy Suzonbought
- Kim Joanne Wendybought
- Do Cuong Vbought
- Do Cuong Vbought
- Do Cuong Vbought
80 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in BIVI.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
